Sanofi wins FDA TB nod; UCB brings on Daiichi to market Vimpat in Japan;

> Sanofi ($SNY) has won FDA approval for Priftin tablets to treat latent tuberculosis infection. Release (PDF)

> Daiichi Sankyo has teamed up with UCB to commercialize epilepsy treatment Vimpat in Japan. Report

> Ranbaxy and Epirus have launched a biosimilar of Johnson & Johnson's ($JNJ) Remicade in India. More

> The EU has greenlighted Astellas' Xtandi for prechemo prostate cancer. Report

> Otsuka says new pickup Avanir's ($AVNR) sales and marketing capabilities can help it create a global CNS company. Release

And Finally... GlaxoSmithKline ($GSK) has named the winners for its drug-hunter challenge. More

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

Roche’s Tecentriq didn't repeat its prior TNBC success when tested in tandem with chemo med paclitaxel in previously untreated metastatic patients.

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.